Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,131,336
  • Shares Outstanding, K 146,759
  • Annual Sales, $ 9,891 M
  • Annual Income, $ 1,293 M
  • EBIT $ 2,377 M
  • EBITDA $ 3,451 M
  • 60-Month Beta 0.15
  • Price/Sales 2.79
  • Price/Cash Flow 8.39
  • Price/Book 1.53

Options Overview Details

View History
  • Implied Volatility 36.02% (+1.03%)
  • Historical Volatility 37.39%
  • IV Percentile 59%
  • IV Rank 22.70%
  • IV High 64.86% on 04/09/25
  • IV Low 27.55% on 01/07/26
  • Expected Move (DTE 6) 6.86 (3.71%)
  • Put/Call Vol Ratio 0.84
  • Today's Volume 951
  • Volume Avg (30-Day) 1,087
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 51,647
  • Open Int (30-Day) 51,755
  • Expected Range 178.01 to 191.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 35 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 3.05
  • Number of Estimates 26
  • High Estimate 4.68
  • Low Estimate 1.66
  • Prior Year 3.02
  • Growth Rate Est. (year over year) +0.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
181.24 +2.00%
on 03/06/26
201.00 -8.02%
on 02/09/26
-16.31 (-8.11%)
since 02/06/26
3-Month
160.36 +15.28%
on 01/20/26
202.41 -8.67%
on 02/06/26
+3.57 (+1.97%)
since 12/05/25
52-Week
110.04 +68.00%
on 04/09/25
202.41 -8.67%
on 02/06/26
+37.50 (+25.45%)
since 03/06/25

Most Recent Stories

More News
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA) New Phase 1b data further illustrate potential of salanersen in SMA,...

BIIB : 184.87 (-1.71%)
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– ...

STOK : 35.48 (+2.40%)
BIIB : 184.87 (-1.71%)
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support...

STOK : 35.48 (+2.40%)
BIIB : 184.87 (-1.71%)
Is Vertex Stock Outperforming the Dow?

Despite underperforming the Dow Jones Industrial Average over the past year, Vertex continues to earn moderate bullish support from analysts.

VRTX : 456.69 (-0.90%)
$DOWI : 47,501.55 (-0.95%)
BIIB : 184.87 (-1.71%)
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine,...

STOK : 35.48 (+2.40%)
BIIB : 184.87 (-1.71%)
3 Value Stocks Walking a Fine Line

3 Value Stocks Walking a Fine Line

PANL : 8.36 (-3.80%)
WEX : 167.07 (+0.58%)
BIIB : 184.87 (-1.71%)
What Are Wall Street Analysts' Target Price for Biogen Stock?

Analysts are maintaining a generally positive outlook on Biogen's shares, noting recent stock strength and solid operational results.

$SPX : 6,740.02 (-1.33%)
IBB : 167.56 (-0.66%)
BIIB : 184.87 (-1.71%)
The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call

The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call

BIIB : 184.87 (-1.71%)
1 Unpopular Stock That Deserves a Second Chance and 2 We Find Risky

1 Unpopular Stock That Deserves a Second Chance and 2 We Find Risky

ASGN : 42.89 (-0.56%)
ALHC : 18.44 (-0.70%)
BIIB : 184.87 (-1.71%)
Biogen Announces Board Chair Transition

CAMBRIDGE, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biogen Inc . (Nasdaq: BIIB) today announced that the Board of Directors has elected Dr. Maria C. Freire as Chair of the Board of Directors, effective...

BIIB : 184.87 (-1.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 192.01
2nd Resistance Point 189.13
1st Resistance Point 187.00
Last Price 184.87
1st Support Level 181.99
2nd Support Level 179.11
3rd Support Level 176.98

See More

52-Week High 202.41
Last Price 184.87
Fibonacci 61.8% 167.12
Fibonacci 50% 156.23
Fibonacci 38.2% 145.33
52-Week Low 110.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar